WARRENDALE, Pa., June 12 /PRNewswire/ -- MEDRAD, INC., has signed a distribution and co-marketing partnership agreement with PETNET Solutions, a fully owned subsidiary of Siemens Medical Solutions USA, Inc. The agreement will enable health care providers to inject Fluorodeoxyglucose (FDG) for Positron Emission Tomography/Computed Tomography (PET/CT) imaging procedures in an innovative, new way. The partnership will leverage MEDRAD's soon to be introduced PET infusion system and multi-dose FDG packaging and delivery from PETNET Solutions. PET/CT Imaging has proven effective in diagnosing and staging certain forms of cancer.
MEDRAD's PET infusion system, to be called Intego(TM), is designed to automatically extract a patient dose from a multi-dose vial and deliver it directly to the patient. The system is mobile and includes dosimetry, shielding, and a touchscreen interface -- all with precision, flexibility, and safety in mind.
PETNET Solutions has agreed to provide FDG to customers throughout its extensive, cyclotron-based radiopharmacy network in multi-dose vials and specially designed vial shields, which will allow for easy integration with MEDRAD's new system.
Michael Reitermann, chief executive officer, Molecular Imaging, Siemens Medical Solutions USA, Inc., commented, "In addition to our traditional delivery method, by providing FDG in multi-dose vials compatible with the MEDRAD PET infusion system across our extensive network, we have the opportunity to help improve the way FDG is being handled and delivered."
Alan Connor, director of global marketing for MEDRAD Molecular Imaging, said, "We are very pleased that PETNET Solutions is the first FDG provider to agree to provide FDG in a manner compatible with the Intego System across its entire network. From the beginning of this project, PETNET Solutions has been instrumental to the development of this system and is dedicated to providing the latest in safety and clinical performance to their customers."
MEDRAD will show the system at the annual Society of Nuclear Medicine (SNM) meeting in New Orleans, Louisiana, on June 13-16.
MEDRAD, INC., is a worldwide leading provider of medical devices and services that enable and enhance imaging procedures of the human body. Used in diagnostic imaging, MEDRAD's product offerings include a comprehensive line of vascular injection systems, magnetic resonance (MR) surface coils and patient care products, and equipment services. Total 2007 revenues were $525 million. MEDRAD is a 2003 recipient of the Malcolm Baldrige National Quality Award, the top honor a U.S. company can receive for quality and business excellence. The company's world headquarters is near Pittsburgh, Pennsylvania, in the United States. MEDRAD is an affiliate of Bayer AG.
The Bayer Group is a global enterprise with core competencies in the fields of healthcare, nutrition and high-tech materials. Bayer HealthCare, a subsidiary of Bayer AG, is one of the world's leading, innovative companies in the healthcare and medical products industry and is based in Leverkusen, Germany. The company combines the global activities of the Animal Health, Consumer Care, Diabetes Care and Pharmaceuticals divisions. The pharmaceuticals business operates under the name Bayer Schering Pharma AG. Bayer HealthCare's aim is to discover and manufacture products that will improve human and animal health worldwide. Find more information at http://www.bayerhealthcare.com.
About PETNET Solutions
PETNET Solutions, a fully owned subsidiary of Siemens Medical solutions, operates the largest PET radiopharmacy network with over 44 radiopharmacies and distribution centers at multiple locations that produce and distribute PET radiopharmaceuticals to hospitals, clinics, and research facilities for PET imaging.
Cautionary statement regarding forward-looking statement.
Certain statements in this press release that are neither reported financial results nor other historical information are forward-looking statements, including but not limited to, statements that are predictions of or indicate future events, trends, plans or objectives. Undue reliance should not be placed on such statements because, by their nature, they are subject to known and unknown risks and uncertainties and can be affected by other factors that could cause actual results and MEDRAD's plans and objectives to differ materially from those expressed or implied in the forward-looking statements. MEDRAD, INC., undertakes no obligation to update publicly or revise any of these forward-looking statements, whether to reflect new information or future events or circumstances or otherwise.
|SOURCE MEDRAD, INC.|
Copyright©2008 PR Newswire.
All rights reserved